Lixte Biotechnology

Yahoo Finance • 18 days ago

LIXTE Biotechnology makes $2.6M initial purchase of digital currency

* LIXTE Biotechnology (NASDAQ:LIXT [https://seekingalpha.com/symbol/LIXT]) said on Wednesday that it has made an initial purchase of cryptocurrencies [https://seekingalpha.com/pr/20228805-lixte-biotechnology-holdings-makes-2_6-million-in... Full story

Yahoo Finance • 18 days ago

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

BOCA RATON, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has made an initial purchase of cryp... Full story

Yahoo Finance • 25 days ago

Lixte Biotechnology appoints new CFO and board members

* Lixte Biotechnology (NASDAQ:LIXT [https://seekingalpha.com/symbol/LIXT]) appointed Peter Stazzone as chief financial officer. * Lourdes Felix and Guy Primus joined LIXTE’s board of directors. * Former CFO Robert Weingarten and boar... Full story

Yahoo Finance • last month

24/7 Market News: LIXTE Showcases LB-100 at First Global Conference on Oncogenic Signaling Activation as Cancer Therapy

DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in C... Full story

Yahoo Finance • last month

24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets

DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a... Full story

Yahoo Finance • last month

24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100

DENVER, Aug. 19, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits the LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT... Full story

Yahoo Finance • last month

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

Breakthrough Protein Phosphatase 2A inhibitor LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer 24/7 Market News Issues Corrected Information on Previously issued Press Release with... Full story

Yahoo Finance • last month

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a cli... Full story

Yahoo Finance • 2 months ago

Wednesday's session: gap up and gap down stocks

The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. [gap] GAP UP STOCKS TICKER CHANGE COMMENT BSLK [https://www.chartmill.com/stock/quote/BS... Full story

Yahoo Finance • 2 months ago

24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy

DENVER, Aug. 13, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, reports that LIXTE Biotechnology Holdings (Nasdaq: LIXT), a c... Full story

Yahoo Finance • 2 months ago

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

PASADENA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved... Full story

Yahoo Finance • 2 months ago

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

Lixte Biotechnology Holdings, Inc. PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it has... Full story

Yahoo Finance • 3 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $1.5 Million Registered Direct Offering

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (N... Full story

Yahoo Finance • 3 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited in... Full story

Yahoo Finance • 3 months ago

Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.’s $5.0 Million Private Placement

New York, NY, July 08, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $5.0 million private placement for Lixte Biotechnology Holdings, Inc. (NASDAQ: L... Full story

Yahoo Finance • 3 months ago

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

PASADENA, CALIF, July 02, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced the closing of a private placement with accredited investors f... Full story

Yahoo Finance • 3 months ago

Lixte Biotechnology secures $5 million in private placement

PASADENA, Calif. - Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT), a clinical-stage pharmaceutical company with a market capitalization of $3.17 million, has entered into a definitive agreement with accredited investors for a $5 million... Full story

Yahoo Finance • 3 months ago

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

PASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the “Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive... Full story

Yahoo Finance • 3 months ago

Lixte Biotechnology files to sell 5.26M shares of common stock, warrants

* Lixte Biotechnology (NASDAQ:LIXT [https://seekingalpha.com/symbol/LIXT]) has filed to sell 5.26M shares of common stock, warrants. * Source: Filing  [https://seekingalpha.com/filing/10108907] MORE ON LIXTE BIOTECHNOLOGY HOLDINGS, I... Full story

Yahoo Finance • 2 years ago

LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA, Sept. 20, 2023 (GLOBE NEW... Full story